Compare FINV & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | AVLN |
|---|---|---|
| Founded | 2007 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2017 | 2026 |
| Metric | FINV | AVLN |
|---|---|---|
| Price | $3.37 | $38.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.10 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 170.6K |
| Earning Date | 05-19-2026 | N/A |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.58 | N/A |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.22 | $24.90 |
| 52 Week High | $8.05 | $40.17 |
| Indicator | FINV | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 62.07 |
| Support Level | N/A | $26.38 |
| Resistance Level | $5.17 | $40.08 |
| Average True Range (ATR) | 0.22 | 1.98 |
| MACD | -0.08 | -0.22 |
| Stochastic Oscillator | 12.72 | 72.20 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.